Key facts
- Origin (Diagnostic Equipment)’s last known valuation is $165.2M (Dec 2024).
- It has raised $39.0M; the latest was Later Stage VC ($12.5M) in Dec 2024.
- Notable investors include CSVE Ventures, 2050 Capital, CPTLNYC, Chicago Booth Angels Network, Conan Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Origin (Diagnostic Equipment)
- ·The full record, as it builds
Funding rounds
No funding rounds for Origin (Diagnostic Equipment) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Origin (Diagnostic Equipment)
Manufacturer of genomic diagnostic tests designed to detect and monitor gastrointestinal diseases. The company's platform offers rectal mucus sampling, multi-signal molecular analysis, and rapid test procedures, enabling healthcare providers to identify gastrointestinal conditions and support clinical decision-making.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2003
- Employees
- 42
- Website
- originsciences.com/
- Ownership
- Privately Held (backing)
Origin (Diagnostic Equipment) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Origin (Diagnostic Equipment) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Origin (Diagnostic Equipment) in its N-PORT filings yet. We sweep new filings monthly.